Tharimmune (NASDAQ:THAR) Stock, Quote.Headers.trade-ideas

Tharimmune

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Medicine

News

Movers

THAR

Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver Disease (AASLD) meeting. Here&#39;s what you need to know.

What&#39;s Going On With Tharimmune Shares Monday?

Oil Price Photo by William Potter on Shutterstock

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

APDN

OMCL

RDDT

SVMH

Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast

Wall Street

Earnings

S&amp;P 500 Edges Lower; US Crude Oil Inventories Fall

Tharimmune Inc

Tharisa PLC

Biotech

Legal

Press Releases

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Triller Group Inc. (NASDAQ: ILLR) Reversing as Shorts Run for Cover – see more stocks inside…

New Jersey-Based Biotech Company Finds Massive Mid-Week Success Following "Positive Feedback"

Events

Tharimmune Announces Upcoming Conference Presentations

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Offerings

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Tharimmune to Present at the Microcap Conference 2025

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

CRDL

GOOG

ILLR

PRSO

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Bone Biologics

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Entero Therapeutics

Genprex

GRI Bio

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Oragenics

Onconetix

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Synaptogenix

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Theriva Biologics

Rodman & Renshaw

Comments

Tharimmune

Tharimmune (NASDAQ:THAR) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga